The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-13 and is reviewed periodically as new material appears.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
The defence submitted that there was no case to answer on the air‑embolism allegations, arguing that the prosecution's experts lacked sufficient clinical experience, that the research basis for air embolism was inconsistent, and that expert descriptions of the condition varied. Goss ruled that there was "a sufficient body of accepted medical opinion" to allow the allegation to be considered by the jury.
The chestnut or sorrel color, genetically considered "red", is caused by one of two recessive alleles at the extension locus (genetics). Extension has three known alleles: the wildtype "E", necessary for the bay and black coat colors, plus two mutations "e" and "ea", both of which are capable of causing the chestnut color. Each individual horse has two copies of the extension gene. If either copy is "E", then the horse will be bay- or black-based. But if the two copies are any combination of "e" and "ea" (e/e, e/ea, or ea/ea), then the horse will be red-based. Alternate extension "ea" is rare and there is no known difference in appearance between it and the more common "e". Because the red color is recessive, two bay or black parents can produce a chestnut foal if both carry "e" or "ea". However, two chestnut parents cannot produce a bay or black foal. The extension locus (genetics) is found on chromosome 3 (ECA3) and is part of the gene that codes for the equine melanocortin 1 receptor (MC1R). This receptor is part of a signalling pathway which when activated causes melanocytes to produce eumelanin, or black pigment, instead of pheomelanin, or red pigment. The two mutant alleles "e" and "ea" code for dysfunctional receptors unable to activate this pathway, so absent "E", only red pigment can be produced. At least one copy of the functional "E" allele is required to activate the signal and produce black pigment.
== Motivation == While one-place studies in Britain are often pursued for simple enjoyment, amateur one-place studies in continental nations sometimes assert their value to social science. The introduction to a recent survey of German one-place studies listed the following topics that were likely to benefit from the research:
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}-\int \limits _{\Omega }\mu \Delta \mathbf {u} \cdot \mathbf {v} &=\int \limits _{\Omega }\mu \nabla \mathbf {u} \cdot \nabla \mathbf {v} -\int \limits _{\partial \Omega }\mu {\frac {\partial \mathbf {u} }{\partial {\hat {\mathbf {n} }}}}\cdot \mathbf {v} \\\int \limits _{\Omega }\nabla p\cdot \mathbf {v} &=-\int \limits _{\Omega }p\nabla \cdot \mathbf {v} +\int \limits _{\partial \Omega }p\mathbf {v} \cdot {\hat {\mathbf {n} }}\end{aligned}}}
=== Environmental impact === Refinement of sulfidic zinc ores produces large volumes of sulfur dioxide and cadmium vapor. Smelter slag and other residues contain significant quantities of metals. About 1.1 million tonnes of metallic zinc and 130 thousand tonnes of lead were mined and smelted in the Belgian towns of La Calamine and Plombières between 1806 and 1882. The dumps of the past mining operations leach zinc and cadmium, and the sediments of the Geul River contain non-trivial amounts of metals. About two thousand years ago, emissions of zinc from mining and smelting totaled 10 thousand tonnes a year. After increasing 10-fold from 1850, zinc emissions peaked at 3.4 million tonnes per year in the 1980s and declined to 2.7 million tonnes in the 1990s, although a 2005 study of the Arctic troposphere found that the concentrations there did not reflect the decline. Man-made and natural emissions occur at a ratio of 20 to 1. Zinc in rivers flowing through industrial and mining areas can be as high as 20 ppm. Effective sewage treatment greatly reduces this; treatment along the Rhine, for example, has decreased zinc levels to 50 ppb. Concentrations of zinc as low as 2 ppm adversely affects the amount of oxygen that fish can carry in their blood.
Elion (1918–1999), American biochemist and recipient of the 1988 Nobel Prize in Physiology or Medicine for innovative methods of rational drug design Conrad Elvehjem (1901–1962), American biochemist who identified two vitamins, nicotinic acid (niacin) and nicotinamide Harry Julius Emeléus (1903–1993), British inorganic chemist known for work on fluorine chemistry Gladys Anderson Emerson (1903–1984), American chemist and early nutritionist, and the first person to isolate Vitamin E Emil Erlenmeyer (1825–1909), German chemist known for the early development of the theory of chemical structure and formulating the Erlenmeyer rule. Richard R. Ernst (1933–2021), Swiss physical chemist, 1991 Nobel Prize in Chemistry for the development of Fourier transform nuclear magnetic resonance spectroscopy Gerhard Ertl (born 1936), German physical chemist who laid the foundation of modern surface chemistry, 2007 Nobel prize in chemistry Margaret C. Etter (1943–1992), American chemist and developer of solid state chemistry for crystalline organic compounds Hans von Euler-Chelpin (1873–1964), Swedish chemist, winner of the 1929 Nobel Prize in Chemistry for work on the fermentation of sugar and enzymes Henry Eyring (1901–1981), Mexico-born American theoretical chemist known for the absolute rate theory of chemical reactions
Sources: en.wikipedia.org
Non-pathogenic organisms can become pathogenic given specific conditions, and even the most virulent organism requires certain circumstances to cause a compromising infection. Some colonizing bacteria, such as Corynebacteria sp. and Viridans streptococci, prevent the adhesion and colonization of pathogenic bacteria and thus have a symbiotic relationship with the host, preventing infection and speeding wound healing.
=== Marxism and socialism === In a 2001 interview with Reason, Hitchens said he became a Marxist and a Trotskyist in his teens, beliefs that further developed during his time at Balliol College, Oxford. In 1966, he was demonstrating in Trafalgar Square against the Vietnam War. In 1967, he joined the International Socialists while at Balliol College, Oxford. Under the influence of Peter Sedgwick, who translated the writings of Russian revolutionary and Soviet dissident Victor Serge, Hitchens forged an ideological interest in Trotskyist and anti-Stalinist socialism. Shortly after he joined "a small but growing post-Trotskyist Luxemburgist sect". This organisation is now known as the Alliance for Workers' Liberty. He became a socialist "largely [as] the outcome of a study of history, taking sides ... in the battles over industrialism and war and empire." He was also drawn into the political left by his anger over the Vietnam War, nuclear weapons, racism and "oligarchy", including that of "the unaccountable corporation." He also said in the same interview with Reason that he could no longer say "I am a socialist". Socialists, he claimed, had ceased to offer a positive alternative to the capitalist system. In a June 2010 interview with The New York Times, he stated that "I still think like a Marxist in many ways. I think the materialist conception of history is valid. I consider myself a very conservative Marxist".
The European bone skipper, Thyreophora cynophila, is an obligately necrophagous fly. It relies on carrion bone marrow in the first stage of its life cycle. Many other types of fly are facultatively necrophagous. Examples commonly found on land include blow flies, flesh flies, muscid flies, black soldier flies, ensign flies and thread-horns. Other necrophagous flies, for example black flies and lake flies, are semi-aquatic. Types of carrion fed upon include wildlife, livestock and poultry carcasses, slaughterhouse and fishing discards, and human bodies.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.